

## IMAGION BIOSYSTEMS LIMITED

ASX: IBX

22 December 2023

### Issue of Managing Director Options

MELBOURNE and SAN DIEGO — Imagion Biosystems Limited (ASX: IBX) today lodged an Appendix 3G confirming the issue of 187,500 options to Dr. Isaac Bright upon his six-month anniversary pursuant to his Executive Employment Agreement. The options have an exercise price of \$0.4041 being equal to the 30-day VWAP up to and including 20 December 2023 and expire in ten years. The issue of options were approved by shareholders at the Extraordinary General Meeting held on 13<sup>th</sup> November 2023.

Also attached to this announcement are Dr. Bright's Initial Director's Interest Notice (Appendix 3X) and Change in Director's Interest Notice (Appendix 3Y). The Appendix 3X (showing NIL interests held by Dr. Bright) was due to be lodged on 13 November 2023 (Dr. Bright's date of appointment) and was missed due to an administrative oversight.

— ENDS —

### About Imagion Biosystems

Established in 2017 and headquartered in the San Diego, California, US, Imagion Biosystems is an ASX-listed company dedicated to developing innovative medical imaging technologies for various cancer types. Imagion Biosystems is advancing clinical development of its MagSense<sup>®</sup> platform technology to revolutionize cancer diagnosis, introducing molecular imaging to MRI. The Company's lead program has demonstrated its innovative technology embodied in MagSense<sup>®</sup> HER2 Imaging Agent (MSH2IA) is safe and well-tolerated in patients diagnosed with HER2+ breast cancer. Imagion Biosystems' MagSense<sup>®</sup> pipeline includes prostate cancer, ovarian cancer, pancreatic cancer, and brain cancer programs.

For more information, visit <https://imaginationbiosystems.com/investor-hub/>

### Imagion Biosystems Interactive Investor Hub

Engage with us directly by asking questions, watching video summaries, and seeing what other shareholders have to say about this and past announcements at our Investor Hub:

<https://investorhub.imaginationbiosystems.com/>





### **Authorisation & Additional information**

This announcement was authorised by the Disclosure Committee of Imagion Biosystems Limited.

#### **Australian Media & Investor Relations:**

Geoff Hollis, CFO and Company Secretary  
[geoff.hollis@imagionbio.com](mailto:geoff.hollis@imagionbio.com)  
+61 438 168 008

#### **U.S. Media Contact**

Casie Ost  
[casie.ost@imagionbio.com](mailto:casie.ost@imagionbio.com)  
+1-619-693-4428

**Imagion Biosystems Ltd.**

ASX:IBX ACN 616 305 027

[www.imagionbiosystems.com](http://www.imagionbiosystems.com)



# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr. Isaac Bright
<b>Date of appointment</b>	13 November 2023

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b> NIL
--

+ See chapter 19 for defined terms.

## Appendix 3X Initial Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of Securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest.	NIL

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>No. and class of securities to which interest relates</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Imagion Biosystems Limited</b>
<b>ABN</b>	<b>42 616 305 027</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr. Isaac Bright
<b>Date of last notice</b>	22 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	20 December 2023
<b>No. of securities held prior to change</b>	NIL
<b>Class</b>	Director options
<b>Number acquired</b>	187,500
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. of securities held after change</b>	187,500 options
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of director options approved at EGM held on 13 November 2023

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.